Relay Therapeutics Sees Unusually Large Options Volume

Shares of the biotech company traded down 0.4% on Monday amid the spike in call options activity.

Mar. 16, 2026 at 4:19pm

Got story updates? Submit your updates here. ›

Relay Therapeutics, Inc. (NASDAQ:RLAY) saw unusually high options trading volume on Monday, with investors purchasing 5,148 call options on the stock. This represents a 1,428% increase compared to the average daily volume of 337 call options. Shares of the clinical-stage biotech company focused on precision therapies for oncology traded down 0.4% on the day.

Why it matters

The spike in call options activity on Relay Therapeutics' stock suggests investors may be betting on the company's future performance and potential upside. As a clinical-stage biotech firm, Relay Therapeutics' stock can be volatile and options trading can provide a way for investors to speculate on the company's drug development pipeline and potential regulatory approvals.

The details

Relay Therapeutics, which is headquartered in Cambridge, Massachusetts, has a market capitalization of $1.84 billion. The company's stock has traded in a range of $1.77 to $11.49 over the past 52 weeks, closing at $10.32 on Monday. Relay Therapeutics reported quarterly earnings in February, posting a loss of $0.32 per share but exceeding analyst estimates.

  • Relay Therapeutics saw the unusually high options volume on Monday, March 16, 2026.

The players

Relay Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing precision therapies for oncology using its proprietary drug discovery platform.

Got photos? Submit your photos here. ›

The takeaway

The spike in call options activity on Relay Therapeutics suggests investors see potential upside in the biotech company's stock, though the company's volatile share price and status as a clinical-stage firm means the options trading could also reflect speculative bets on the company's future drug development progress and regulatory approvals.